Aripiprazole in Depersonalization Disorder Comorbid With Major Depression and Obsessive-Compulsive Disorder

“…Studies were small and heterogenous, mainly including participants with BPD. 111 , 112 , 126 One RCT (n = 51) compared asenapine to olanzapine 5–10 mg/day for 12 weeks in BPD, demonstrating improvement in BPD-related dissociation symptoms with both medications. The two small lamotrigine studies focused on DPD with mixed results; the positive case series used up to 600 mg per day over 6–21 months.…”

Section: Resultsmentioning

confidence: 99%

Survival, Attachment, and Healing: An Evolutionary Lens on Interventions for Trauma-Related Dissociation

Burback,

Forner,

Winkler

et al. 2024

PRBM

View full text Add to dashboard Cite

“…Описан случай быстрого разрешения кататонии в рамках монополярной депрессии на фоне лечения арипипразолом [52]. Также сообщается о нескольких случаях редукции проявлений деперсонализации в рамках депрессии, которые обычно тяжело поддаются фармакологическому лечению [53].…”

Section: особенности клинической эффективностиunclassified

Use of the Third-Generation Atypical Antipsychotic Aripiprazole (Zylaxera®) for Treatment of Depressive States in Schizophrenia: Efficacy and Safety Study

Олейчик¹,

Баранов²,

Shishkovskaya³

2023

Psychiatry

View full text Add to dashboard Cite

Background: Aripiprazole, among other atypical antipsychotics, is recommended as a drug for maintenance therapy in schizophrenia in cases in which the patient is identiﬁed as having depressive symptoms. At the same time, depression in schizophrenia is not listed as a separate indication for Aripiprazole, its antidepressant properties are considered only in the recommendations for the treatment of bipolar depression and augmentation of antidepressant therapy in recurrent depressive disorder. There are no works characterizing the efﬁcacy of the drug in depression in patients with schizophrenia, as well as evaluating the spectrum of its antidepressant action in such conditions.Objective of the study: to examine the therapeutic efﬁcacy and safety of Aripiprazole (Zylaxera®) in the augmentation therapy of moderate to severe depressive states in patients with schizophrenia.Patients and methods: the efﬁcacy and safety of Aripiprazole (Zylaxera®) augmentation therapy with 5–20 mg daily dose for 6 weeks was studied in 72 patients aged 18 to 47 years (all women) with depressive states of at least 17 Hamilton Scale scores in remitted schizophrenia, postchizophrenic depression and schizotypal disorder (F20.01 + F32.1–2; F20.04; F21.3–4 + F32.1–2). The HDRS-21, CGI, and UKU scales were used for psychometric assessment.Results: the effectiveness of augmentation of antidepressant therapy with Zylaxera® was revealed in the majority of patients: the rate of responders as evaluated by the HDRS-21 scale (reduction of severity of depressive disorders by 50% or more) was 67.2% and 71.4% for the CGI scale. At the same time, it was established that the group of responders had a certain similarity in terms of psychopathological structure of depressive states.Conclusion: it has been established, that in patients suffering from schizophrenia Zylaxera® has a distinct efﬁcacy in augmentation of antidepressant therapy and has a favorable tolerability proﬁle. The maximum efﬁcacy of the drug within the framework of such use is observed in depressive states with predominance of negative affectivity.

show abstract

Aripiprazole in Depersonalization Disorder Comorbid With Major Depression and Obsessive-Compulsive Disorder

Cited by 4 publications

References 15 publications

Complex Trauma in Adolescents and Adults

Complex Trauma in Adolescents and Adults

Survival, Attachment, and Healing: An Evolutionary Lens on Interventions for Trauma-Related Dissociation

Use of the Third-Generation Atypical Antipsychotic Aripiprazole (Zylaxera®) for Treatment of Depressive States in Schizophrenia: Efficacy and Safety Study

Contact Info

Product

Resources

About